Brief: Corvus Pharmaceuticals Provides Business Update And Reports First Quarter 2023 Financial Results

Corvus Pharmaceuticals

08/05/2023 23:17

May 8 (Reuters) - Corvus Pharmaceuticals Inc  CRVS.O :
    * CORVUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND
REPORTS
FIRST QUARTER 2023 FINANCIAL RESULTS
    * CORVUS- UPDATED INTERIM RESULTS FROM CPI-818 PHASE 1/1B
CLINICAL
TRIAL CONTINUES TO SUPPORT POTENTIAL OF ITK INHIBITION, ALC
BIOMARKER IN T CELL LYMPHOMA
    * CORVUS PHARMACEUTICALS - EXPECTS FULL YEAR 2023 NET CASH
USED IN
OPERATING ACTIVITIES TO BE BETWEEN ABOUT $19 MILLION AND $22
MILLION
    * CORVUS PHARMACEUTICALS - AS OF MARCH 31, 2023, CO HAD
CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $34.5 MILLION
    * CORVUS PHARMACEUTICALS - BASED ON CURRENT PLANS, CO
EXPECTS ITS
CASH TO FUND OPERATIONS INTO 2024
    * CORVUS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.17

Source text for Eikon:  ID:nGNX7dZ0Ll 
Further company coverage:  CRVS.O 

 ((Reutersbriefs@thomsonreuters.com;))